Cost‐effectiveness of sodium‐glucose cotransporter‐2 inhibitors in the treatment of diabetic nephropathy in Japan
Main finding · Incremental cost-effectiveness ratioResult — go to the resultIncremental cost-effectiveness ratio 654 309 JPY per QALYAuthors' conclusion
The SGLT2 inhibitor treatment appeared to be cost-effective for the overall population of our study and particularly for younger patients (<70 years old). For older patients (≥70 years old), the cost-effectiveness was less clear and may require further evaluation. Decision-makers should consider this age-based heterogeneity when making recommendations about SGLT2 inhibitor treatment.
Study context
- Population
- People with diabetic nephropathy initiating pharmacotherapy, Japanese clinical practice; inputs from CREDENCE, Japanese Society for Dialysis Research survey and Japanese Health Insurance Claims Data
- Exposure
- SGLT2i plus conventional treatment vs conventional treatment alone
- Outcome
- Cost-effectiveness based on quality-adjusted life-years (QALYs) and healthcare costs (incremental cost-effectiveness ratio)
Methodological detailspopulation-based Monte Carlo simulation, state transition model, one-way and probabilistic sensitivity analyses
- Population-based Monte Carlo simulation
- State transition model
- One-way and probabilistic sensitivity analyses
Main finding
Incremental cost-effectiveness ratio
Incremental cost-effectiveness ratio
654 309 JPY per QALY
As reported in the abstract
Observational data: associations, not effects.
Further findings
Events prevented per 100 000 treated with SGLT2i + conventional treatment
- Deaths prevented
- 2234
- Fewer HF cases
- 5793
- Fewer MI and stroke events
- 3967
Sensitivity analysis
- Results robust for patients aged under 70 years
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →